Effects of once-weekly semaglutide vs canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial

被引：0
|
作者：
McCrimmon, R. J. [1 ]
Catarig, A. [2 ]
Frias, J. P. [3 ]
Lausvig, N. L. [2 ]
le Roux, C. W. [4 ]
Thielke, D. [2 ]
Lingvay, I. [5 ]
机构：
[1] Univ Dundee, Dundee, Scotland
[2] Novo Nordisk AS, Soborg, Denmark
[3] Natl Res Inst, Los Angeles, CA USA
[4] Univ Coll Dublin, Dublin, Ireland
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
54
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [21] The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes
    Kapitza, Christoph
    Dahl, Kirsten
    Jacobsen, Jacob Bonde
    Axelsen, Mads Buhl
    Bergan, Eirik Quamme
    Flint, Anne
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S127 - S128
  • [22] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [23] Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
    Tuttle, Katherine R.
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Khunti, Kamlesh
    Rasmussen, Soren
    Sokareva, Ekaterina
    Cherney, David Z.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2006 - 2015
  • [24] COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING
    Liu, A.
    Bech, P.
    Fridhammar, A.
    Nilsson, A.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2020, 23 : S114 - S114
  • [25] Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Frias, Juan P.
    Kumar, Harish
    Lausvig, Nanna L.
    le Roux, Caret W.
    Thielke, Desiree
    Viljoen, Adie
    McCrimmon, Rory J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 834 - 844
  • [26] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with Type 2 diabetes (SUSTAIN 2)
    Ahren, B.
    Comas, L. M.
    Kumar, H.
    Sargin, M.
    Karsbol, J. D.
    Jacobsen, S. H.
    Chow, F.
    DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [27] Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)
    Ahren, B.
    Comas, L. Masmiquel
    Kumar, H.
    Sargin, M.
    Karsbol, J. Derving
    Jacobsen, S. Hald
    Chow, F.
    DIABETOLOGIA, 2016, 59 : S365 - S365
  • [28] Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes
    Evans, Marc
    Johansen, Pierre
    Vrazic, Hrvoje
    DIABETES, 2018, 67
  • [29] Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes
    Tuchscherer, Rhianna M.
    Thompson, Angela M.
    Trujillo, Jennifer M.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (12) : 1224 - 1232
  • [30] Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5)
    Rodbard, H.
    Lingvay, I.
    Reed, J.
    de la Rosa, R.
    Rose, L.
    Sugimoto, D.
    Araki, E.
    Chus, P. -L.
    Wijayasingh, N.
    Norwood, P.
    DIABETOLOGIA, 2016, 59 : S364 - S365
12345